-
KGK Sciences And Halucenex Sign Contract For Phase II Clinical Trial On Psilocybin For PTSD
Thursday, July 21, 2022 - 2:24pm | 375KGK Sciences Inc., a subsidiary company of psychedelics healthcare researcher and provider Wellbeing Digital Sciences Inc. (OTC: KONEF), has entered into a research services agreement with Halucenex Life Sciences Inc., a psychedelics subsidiary of Creso Pharma (OTC: COPHF) developing phase 2...